Bone Biologics (BBLG) 10-Q 14 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 09, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-40899
Entity Registrant Name	Bone Biologics Corporation
Entity Central Index Key	0001419554
Entity Tax Identification Number	42-1743430
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Burlington Woods Drive
Entity Address, Address Line Two	Ste 100
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	(781)
Local Phone Number	552-4452
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,100,489
Common stock, $0.001 par value per share
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	BBLG
Security Exchange Name	NASDAQ
Warrants to Purchase Common stock, $0.001 par value per share
Title of 12(b) Security	Warrants to Purchase Common stock, $0.001 par value per share
Trading Symbol	BBLGW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 3,227,634	$ 3,026,569
Advances on research and development contract services	328,844	328,844
Prepaid insurance	273,096	372,350
Prepaid expenses	10,000	10,000
Total current assets	3,839,574	3,737,763
Total assets	3,839,574	3,737,763
Current Liabilities
Accounts payable and accrued expenses	146,186	360,662
Accrued legal settlement		414,989
Warrant liability	18,440	55,751
Total current liabilities	164,626	831,402
Total liabilities	164,626	831,402
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,016,489 and 534,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,016	534
Additional paid-in capital	85,448,860	83,814,785
Accumulated deficit	(81,774,928)	(80,908,958)
Total stockholders’ equity	3,674,948	2,906,361
Total liabilities and stockholders’ equity	$ 3,839,574	$ 3,737,763

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,016,489	534,238
Common stock, shares outstanding	1,016,489	534,238

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues
Operating expenses
Research and development	245,625	2,590,645
General and administrative	657,911	556,892
Total operating expenses	903,536	3,147,537
Loss from operations	(903,536)	(3,147,537)
Other income (expenses)
Change in fair value of warrant liability	37,311	(562,918)
Interest income	255	556
Total other income (expenses)	37,566	(562,362)
Net loss	$ (865,970)	$ (3,709,899)
Weighted average shares outstanding - basic	660,928	67,211
Weighted average shares outstanding - diluted	660,928	67,211
Loss per share - basic	$ (1.31)	$ (55.20)
Loss per share - diluted	$ (1.31)	$ (55.20)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 64	$ 77,907,471	$ (71,960,227)	$ 5,947,308
Balance, shares at Dec. 31, 2022	63,820
Fair value of vested stock options issued to employees and directors		44,764		44,764
Net Loss			(3,709,899)	(3,709,899)
Exercise of warrants	$ 6	(6)
Exercise of warrants, shares	5,837
Extinguishment of warrant liability upon exercise of warrants		490,226		490,226
Balance at Mar. 31, 2023	$ 70	78,442,455	(75,670,126)	2,772,399
Balance, shares at Mar. 31, 2023	69,657
Balance at Dec. 31, 2023	$ 534	83,814,785	(80,908,958)	2,906,361
Balance, shares at Dec. 31, 2023	534,238
Fair value of vested stock options issued to employees and directors		52,681		52,681
Options issued to settle accrued bonus		77,400		77,400
Proceeds from sale of common stock in public offering, net of offering costs of $490,227	$ 345	1,503,994		1,504,339
Proceeds from sale of common stock in public offering, net of offering costs, shares	344,938
Exercise of pre-funded warrants	$ 137			137
Exercise of prefunded warrants, shares	137,313
Net Loss			(865,970)	(865,970)
Balance at Mar. 31, 2024	$ 1,016	$ 85,448,860	$ (81,774,928)	$ 3,674,948
Balance, shares at Mar. 31, 2024	1,016,489

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2024 USD ($)
Common Stock [Member]
Offering costs	$ 490,227

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (865,970)	$ (3,709,899)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	52,681	44,764
Change in fair value of warrant liability	(37,311)	562,918
Changes in operating assets and liabilities:
Advances on research and development contract services		267,789
Prepaid insurance	99,254	93,702
Accounts payable and accrued expenses	(137,076)	41,618
Research and development contract liabilities		1,349,116
Accrued legal settlement	(414,989)
Net cash used in operating activities	(1,303,411)	(1,349,993)
Cash flows from financing activities
Proceeds from sale of common stock units in public offering, net of offering costs	1,504,476
Net cash provided by financing activities	1,504,476
Net increase (decrease) in cash	201,065	(1,349,993)
Cash, beginning of period	3,026,569	7,538,312
Cash, end of period	3,227,634	6,188,319
Supplemental information
Income taxes paid
Noncash investing and financing activities
Options issued to settle accrued bonus	$ 77,400

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (865,970)	$ (3,709,899)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company

The Company	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., (“Merger Sub”), and Bone Biologics, Inc., Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation. On September 22, 2014, the Company changed its name to “Bone Biologics Corporation” and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on September 9, 2004. The Company is a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to the Company through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval application before it can be commercialized in the United States. The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials. The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company. Reverse stock splits On June 5, 2023, the Company filed an amendment to its certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-30 reverse stock split of its outstanding common stock and warrants On December 14, 2023, the Company filed an amendment to its certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-8 reverse stock split of its outstanding common stock and warrants All share and per share amounts have been retro-actively restated as if the reverse splits occurred at the beginning of the earliest period presented. Going Concern and Liquidity The Company has not generated revenue from operations and since inception to March 31, 2024 has incurred accumulated losses of approximately $ 81.8 6.9 0.9 1.3 At March 31, 2024, we had cash of $ 3.2 On March 6, 2024, the Company completed a public offering generating net proceeds to the Company of $ 1.5 The Company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, or substantially reduce or discontinue its operations entirely. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on the Company’s operations, in the case of debt financing, or cause substantial dilution for its stockholders, in the case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2023 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on February 21, 2024 (the “2023 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023 and notes thereto included in the 2023 Annual Report. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2024 or for any other period. Segment Information The Company operates and reports in one segment, which focuses on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. The Company’s operating segment is reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company’s Chief Executive Officer and President. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of the warrant liability, the valuation of debt and equity instruments, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to the Company’s operations and possible effects to the amount and type of financing available to the Company in the future. Cash Cash primarily consists of bank demand deposits maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000 Research and Development Costs Research and development costs include, but are not limited to, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Research and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are charged to operations as incurred. Payments made pursuant to contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its various clinical trial and research and development contracts on a quarterly basis. Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2024: Schedule of Fair Value Liabilities Measured on Recurring Basic Description Total Level 1 Level 2 Level 3 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 18,440 — — $ 18,440 Total liabilities at fair value $ 18,440 — — $ 18,440 The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2024 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basic Using Unobservable March 31, 2024 Warrant liability Balance as of beginning of period – December 31, 2023 $ 55,751 Change in fair value (37,311 ) Balance as of March 31, 2024 $ 18,440 The Company believes the carrying amount of certain financial instruments, including cash and accounts payable approximate their values based on their short-term nature and are excluded from the fair value tables above. Stock Based Compensation ASC 718, Compensation – Stock Compensation Loss per Common Share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity. Since the effects of outstanding options and warrants are anti-dilutive for the three months ended March 31, 2024 and 2023, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options and warrants as of March 31, 2024 and 2023: Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 March 31, 2024 2023 Warrants 1,324,970 46,912 Stock options 74,151 34,285 Anti dilutive securities 1,399,121 81,197 New Accounting Standards The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

Warrant Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2024
Warrant Liability
Warrant Liability	3. Warrant Liability In October 2022, the Company completed a public equity offering, which included the issuance of 54,174 The warrant liability was valued at the following dates using a Black-Scholes model with the following assumptions: Schedule of Warrant Liability Black-Scholes Model March 31, 2024 December 31, 2023 Warrant liability: Risk-free interest rate 4.35 % 3.94 % Expected volatility 137.59 % 136.25 % Expected life (in years) 3.53 3.78 Expected dividend yield - - Fair Value of warrant liability $ 18,440 $ 55,751 The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company determines expected volatility based upon the historical volatility of the Company’s common stock. The Company does not believe that the future volatility of its common stock over an option’s expected term is likely to differ significantly from the past. The expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The dividend yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Equity	4. Stockholders’ Equity Preferred Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 No Common Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 1,016,489 534,238 On March 6, 2024, the Company sold and issued, in a public offering (the “March Offering”), 119,000 119,000 2.56 662,251 662,251 2.559 46,875 6.0 3.20 Concurrent with the closing, 225,938 225,938 In March 2024, 137,313 137,313

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2024
Common Stock Warrants
Common Stock Warrants	5. Common Stock Warrants A summary of warrant activity for the three months ended March 31, 2024 is presented below: Schedule of Warrant Activity Subject to Exercise Number of Weighted Weighted Outstanding as of December 31, 2023 197,844 $ 127.86 4.95 Granted – 2024 1,490,377 1.44 5.00 Forfeited/Expired – 2024 - - - Exercised – 2024 (363,251 ) 0.001 4.93 Outstanding as of March 31, 2024 1,324,970 $ 20.64 4.90 As of March 31, 2024, the Company had outstanding exercisable, but unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 1,512.00 7,620 October 13, 2026 October 2022 $ 388.80 18,058 October 12, 2027 October 2022 $ 324.00 18,846 October 12, 2027 October 2022 $ 0.00 2,393 October 12, 2027 November 2023 $ 6.40 8,543 November 16, 2028 November 2023 $ 4.16 142,384 May 21, 2029 March 2024 $ 2.43 781,251 March 6, 2029 March 2024 – prefunded warrants $ 0.001 299,000 March 6, 2029 March 2024 $ 3.20 46,875 March 6, 2029 Total outstanding warrants at March 31, 2024 1,324,970 Based on a fair market value of $ 2.15 301,393 647,696

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	6. Stock-based Compensation 2015 Equity Incentive Plan The Company has 629,489 5 Awards may be granted under the 2015 Equity Incentive Plan to the Company’s employees, including officers, director or consultants, and its present or future affiliated entities. While the Company may grant incentive stock options only to employees, it may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant. The 2015 Equity Incentive Plan is administered by the Company’s compensation committee. Subject to the provisions of the 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between the Company and the holder of the award. The compensation committee has the authority to construe and interpret the terms of the 2015 Equity Incentive Plan and awards granted under the 2015 Equity Incentive Plan. A summary of stock option activity for the three months ended March 31, 2024 is presented below: Schedule of Stock Option Activity Subject to Exercise Number of Weighted Weighted Aggregate Outstanding as of December 31, 2023 34,310 $ 236.70 8.62 $ - Granted – 2024 45,515 3.72 3.41 - Forfeited/Expired – 2024 (5,674 ) 54.24 7.94 - Exercised – 2024 - - - - Outstanding as of March 31, 2024 74,151 $ 107.65 5.12 $ - Options vested and exercisable at March 31, 2024 59,419 $ 133.13 4.21 $ - As of March 31, 2024, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 9,540.00 174 December 27, 2025 September 2015 $ 9,540.00 36 December 27, 2025 November 2015 $ 9,540.00 205 December 27, 2025 December 2015 $ 9,540.00 12 December 27, 2025 January 2016 $ 9,540.00 213 January 9, 2026 May 2016 $ 12,300.00 45 May 26, 2026 September 2016 $ 12,300.00 21 May 31, 2026 January 2017 $ 12,300.00 10 January 1, 2027 January 2018 $ 11,820.00 8 January 1, 2028 January 2019 $ 564.00 92 January 1, 2029 October 2021 $ 1,260.00 207 October 26, 2031 January 2022 $ 844.80 111 January 1, 2032 August 2022 $ 387.26 462 August 23, 2032 January 2023 $ 57.60 237 January 25, 2025 September 2023 $ 5.12 26,803 September 12, 2033 January 2024 $ 4.68 8,015 January 8, 2034 January 2024 $ 3.61 37,500 January 17, 2026 Total outstanding options at March 31, 2024 74,151 Based on a fair value of $ 2.15 During the three months ended March 31, 2024, 8,015 34,039 52,681 44,764 37,500 77,400 In January 2024, options exercisable into 5,674 The Company utilized the Black-Scholes option-pricing model. The assumptions used for the three months ended March 31, 2024 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Mode March 31, 2024 Risk free interest rate 3.97 % Expected Volatility 137.91 % Expected life (in years) 5.58 Expected dividend yield 0 % The expected volatility is a measure of the amount by which the Company stock price is expected to fluctuate during the expected term of options granted. The Company determines the expected volatility based upon the historical volatility of our common stock since listing on The Nasdaq Capital Market. The Company does not believe that the future volatility of its common stock over an option’s expected term is likely to differ significantly from the past. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of its common stock from its authorized shares instead of settling such obligations with cash payments. As of March 31, 2024, total unrecognized compensation cost related to unvested stock options was $ 24,253 0.06

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies UCLA TDG Exclusive License Agreement Effective April 9, 2019, the Company entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 and amended through three sets of amendments (as so amended the “Amended License Agreement”) with the UCLA TDG. The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Amended License Agreement, the Regents have continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion by local administration, osteoporosis and trauma applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development. The Company has agreed to pay an annual maintenance fee to UCLA TDG of $ 10,000 3.0 50,000 250,000 0.333 10 20 The Company is obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method: ● $ 100,000 ● $ 250,000 ● $ 500,000 ● $ 1,000,000 The Company is also obligated pay to UCLA TDG a fee (the “Diligence Fee”) of $ 8,000,000 ● Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000; ● Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000; and ● Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000. The Company’s obligation to pay the Diligence Fee will survive termination or expiration of the agreement and it is prohibited from assigning, selling, or otherwise transferring any of its assets related to any Licensed Product unless its Diligence Fee obligation is assigned, sold, or transferred along with such assets, or unless it pays UCLA TDG the Diligence Fee within ten (10) days of such assignment, sale or other transfer of such rights to any Licensed Product. The Company is also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016) such payment to equal the greater of: ● $ 500,000 ● 2 As of March 31, 2024, none of the above milestones has been met. The Company is obligated to diligently proceed with developing and commercializing licensed products under UCLA TDG patents set forth in the Amended License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if it does not meet certain diligence milestone deadlines set forth in the Amended License Agreement. The Company must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Amended License Agreement. The Company has the right to bring infringement actions against third party infringers of the Amended License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at the Company’s expense, be joined involuntarily to the action. The Company is required to indemnify UCLA TDG against any third party claims arising out of its exercise of the rights under the Amended License Agreement or any sublicense. Payments to UCLA TDG under the Amended License Agreement for the three months ended March 31, 2024 and 2023 were $ 10,484 16,606 NASDAQ Panel Decision On September 27, 2023, the Company received a written notice from the Nasdaq notifying the Company that it was not in compliance with the $ 1.00 Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events The Company has evaluated subsequent events through May 14, 2024, the date which the consolidated financial statements were available to be issued. There were no additional subsequent events noted that would require adjustment to or disclosure in these consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2023 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on February 21, 2024 (the “2023 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023 and notes thereto included in the 2023 Annual Report. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2024 or for any other period.
Segment Information	Segment Information The Company operates and reports in one segment, which focuses on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. The Company’s operating segment is reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company’s Chief Executive Officer and President.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of the warrant liability, the valuation of debt and equity instruments, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.
Inflation	Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to the Company’s operations and possible effects to the amount and type of financing available to the Company in the future.
Cash	Cash Cash primarily consists of bank demand deposits maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000
Research and Development Costs	Research and Development Costs Research and development costs include, but are not limited to, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Research and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are charged to operations as incurred. Payments made pursuant to contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its various clinical trial and research and development contracts on a quarterly basis.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2024: Schedule of Fair Value Liabilities Measured on Recurring Basic Description Total Level 1 Level 2 Level 3 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 18,440 — — $ 18,440 Total liabilities at fair value $ 18,440 — — $ 18,440 The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2024 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basic Using Unobservable March 31, 2024 Warrant liability Balance as of beginning of period – December 31, 2023 $ 55,751 Change in fair value (37,311 ) Balance as of March 31, 2024 $ 18,440 The Company believes the carrying amount of certain financial instruments, including cash and accounts payable approximate their values based on their short-term nature and are excluded from the fair value tables above.
Stock Based Compensation	Stock Based Compensation ASC 718, Compensation – Stock Compensation
Loss per Common Share	Loss per Common Share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity. Since the effects of outstanding options and warrants are anti-dilutive for the three months ended March 31, 2024 and 2023, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options and warrants as of March 31, 2024 and 2023: Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 March 31, 2024 2023 Warrants 1,324,970 46,912 Stock options 74,151 34,285 Anti dilutive securities 1,399,121 81,197
New Accounting Standards	New Accounting Standards The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Fair Value Liabilities Measured on Recurring Basic	The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2024: Schedule of Fair Value Liabilities Measured on Recurring Basic Description Total Level 1 Level 2 Level 3 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 18,440 — — $ 18,440 Total liabilities at fair value $ 18,440 — — $ 18,440
Schedule of Warrant Liability Measured Fair Value on a Recurring Basic Using Unobservable	The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2024 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basic Using Unobservable March 31, 2024 Warrant liability Balance as of beginning of period – December 31, 2023 $ 55,751 Change in fair value (37,311 ) Balance as of March 31, 2024 $ 18,440
Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share	The following sets forth the number of shares of common stock underlying outstanding options and warrants as of March 31, 2024 and 2023: Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 March 31, 2024 2023 Warrants 1,324,970 46,912 Stock options 74,151 34,285 Anti dilutive securities 1,399,121 81,197

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2024
Warrant Liability
Schedule of Warrant Liability Black-Scholes Model	The warrant liability was valued at the following dates using a Black-Scholes model with the following assumptions: Schedule of Warrant Liability Black-Scholes Model March 31, 2024 December 31, 2023 Warrant liability: Risk-free interest rate 4.35 % 3.94 % Expected volatility 137.59 % 136.25 % Expected life (in years) 3.53 3.78 Expected dividend yield - - Fair Value of warrant liability $ 18,440 $ 55,751

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Common Stock Warrants
Schedule of Warrant Activity	A summary of warrant activity for the three months ended March 31, 2024 is presented below: Schedule of Warrant Activity Subject to Exercise Number of Weighted Weighted Outstanding as of December 31, 2023 197,844 $ 127.86 4.95 Granted – 2024 1,490,377 1.44 5.00 Forfeited/Expired – 2024 - - - Exercised – 2024 (363,251 ) 0.001 4.93 Outstanding as of March 31, 2024 1,324,970 $ 20.64 4.90
Schedule of Outstanding Vested and Unexercised Common Stock Warrants	As of March 31, 2024, the Company had outstanding exercisable, but unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 1,512.00 7,620 October 13, 2026 October 2022 $ 388.80 18,058 October 12, 2027 October 2022 $ 324.00 18,846 October 12, 2027 October 2022 $ 0.00 2,393 October 12, 2027 November 2023 $ 6.40 8,543 November 16, 2028 November 2023 $ 4.16 142,384 May 21, 2029 March 2024 $ 2.43 781,251 March 6, 2029 March 2024 – prefunded warrants $ 0.001 299,000 March 6, 2029 March 2024 $ 3.20 46,875 March 6, 2029 Total outstanding warrants at March 31, 2024 1,324,970

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2024 is presented below: Schedule of Stock Option Activity Subject to Exercise Number of Weighted Weighted Aggregate Outstanding as of December 31, 2023 34,310 $ 236.70 8.62 $ - Granted – 2024 45,515 3.72 3.41 - Forfeited/Expired – 2024 (5,674 ) 54.24 7.94 - Exercised – 2024 - - - - Outstanding as of March 31, 2024 74,151 $ 107.65 5.12 $ - Options vested and exercisable at March 31, 2024 59,419 $ 133.13 4.21 $ -
Schedule of Outstanding Stock Options	As of March 31, 2024, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 9,540.00 174 December 27, 2025 September 2015 $ 9,540.00 36 December 27, 2025 November 2015 $ 9,540.00 205 December 27, 2025 December 2015 $ 9,540.00 12 December 27, 2025 January 2016 $ 9,540.00 213 January 9, 2026 May 2016 $ 12,300.00 45 May 26, 2026 September 2016 $ 12,300.00 21 May 31, 2026 January 2017 $ 12,300.00 10 January 1, 2027 January 2018 $ 11,820.00 8 January 1, 2028 January 2019 $ 564.00 92 January 1, 2029 October 2021 $ 1,260.00 207 October 26, 2031 January 2022 $ 844.80 111 January 1, 2032 August 2022 $ 387.26 462 August 23, 2032 January 2023 $ 57.60 237 January 25, 2025 September 2023 $ 5.12 26,803 September 12, 2033 January 2024 $ 4.68 8,015 January 8, 2034 January 2024 $ 3.61 37,500 January 17, 2026 Total outstanding options at March 31, 2024 74,151
Schedule of Assumptions Using Black-Scholes Option Pricing Mode	The Company utilized the Black-Scholes option-pricing model. The assumptions used for the three months ended March 31, 2024 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Mode March 31, 2024 Risk free interest rate 3.97 % Expected Volatility 137.91 % Expected life (in years) 5.58 Expected dividend yield 0 %

The Company (Details Narrative)

The Company (Details Narrative) - USD ($)				3 Months Ended
	Mar. 06, 2024	Dec. 14, 2023	Jun. 05, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders' equity, reverse stock split		the Company filed an amendment to its certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-8 reverse stock split of its outstanding common stock and warrants	the Company filed an amendment to its certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-30 reverse stock split of its outstanding common stock and warrants
Accumulated deficit				$ 81,774,928		$ 80,908,958
Operating expenses				6,900,000
Net loss				865,970	$ 3,709,899
Net cash used in operating activities				1,303,411	1,349,993
Cash				3,227,634		$ 3,026,569
Proceeds from sale of common stock in public offering, net of offering costs	$ 1,500,000			$ 1,504,476

Schedule of Fair Value Liabilit

Schedule of Fair Value Liabilities Measured on Recurring Basic (Details) - Fair Value, Recurring [Member]	Mar. 31, 2024 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 18,440
Total liabilities at fair value	18,440
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	18,440
Total liabilities at fair value	$ 18,440

Schedule of Warrant Liability M

Schedule of Warrant Liability Measured Fair Value on a Recurring Basic Using Unobservable (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 55,751
Change in fair value including accrued interest	(37,311)
Ending balance	$ 18,440

Schedule of Anti Dilutive Secur

Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	1,399,121	81,197
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	1,324,970	46,912
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	74,151	34,285

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Mar. 31, 2024 USD ($)
Accounting Policies [Abstract]
Cash FDIC insured amount	$ 250,000
Cash SIPC insured amount	$ 500,000

Schedule of Warrant Liability B

Schedule of Warrant Liability Black-Scholes Model (Details) - Warrant [Member]	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrant liability	$ 18,440	$ 55,751
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	4.35	3.94
Measurement Input Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	137.59	136.25
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	3.53	3.78
Measurement Input Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input

Warrant Liability (Details Narr

Warrant Liability (Details Narrative)	1 Months Ended
	Oct. 31, 2022 shares
Warrant Liability
Issuance of warrant shares	54,174

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - $ / shares		1 Months Ended	3 Months Ended
	Mar. 06, 2024	Mar. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized		20,000,000	20,000,000	20,000,000
Preferred stock, shares issued		0	0	0
Common stock, shares authorized		100,000,000	100,000,000	100,000,000
Common stock, shares outstanding		1,016,489	1,016,489	534,238
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exchange for common stock		137,313	137,313
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering	46,875		344,938
Warrant exchange for common stock	225,938
Common Stock [Member] | March Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering	119,000
Warrants to purchase	119,000
Public offering price	$ 2.56
Offering price percentage	6%
Public offering price	3.20
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of warrants	225,938	137,313
Warrant [Member] | March Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering	662,251
Warrants to purchase	662,251
Public offering price	$ 2.559

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Common Stock Warrants
Number of Warrants, Outstanding | shares	197,844
Weighted Average Exercise Price, Outstanding | $ / shares	$ 127.86
Weighted Average Life (Years), Outstanding	4 years 11 months 12 days
Number of Warrants, Granted | shares	1,490,377
Weighted Average Exercise Price, Granted | $ / shares	$ 1.44
Weighted Average Life (Years), Granted	5 years
Number of Warrants, Forfeited/Expired | shares
Weighted Average Exercise Price ,Forfeited/Expired | $ / shares
Number of Warrants, Exercised | shares	(363,251)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.001
Weighted Average Life (Years), Exercised	4 years 11 months 4 days
Number of Warrants, Outstanding | shares	1,324,970
Weighted Average Exercise Price, Outstanding | $ / shares	$ 20.64
Weighted Average Life (Years), Outstanding	4 years 10 months 24 days

Schedule of Outstanding Vested

Schedule of Outstanding Vested and Unexercised Common Stock Warrants (Details) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	1,324,970	197,844
October 2021 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 1,512
Total outstanding warrants	7,620
Expiration date	Oct. 13, 2026
October 2022 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 388.80
Total outstanding warrants	18,058
Expiration date	Oct. 12, 2027
October 2022-1 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 324
Total outstanding warrants	18,846
Expiration date	Oct. 12, 2027
October 2022-2 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0
Total outstanding warrants	2,393
Expiration date	Oct. 12, 2027
November 2023 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 6.40
Total outstanding warrants	8,543
Expiration date	Nov. 16, 2028
November 2023-1 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 4.16
Total outstanding warrants	142,384
Expiration date	May 21, 2029
March 2024 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 2.43
Total outstanding warrants	781,251
Expiration date	Mar. 06, 2029
March 2024-1 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.001
Total outstanding warrants	299,000
Expiration date	Mar. 06, 2029
March 2024-2 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 3.20
Total outstanding warrants	46,875
Expiration date	Mar. 06, 2029

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	Mar. 31, 2024 USD ($) $ / shares shares
Common Stock Warrants
Fair market value | $ / shares	$ 2.15
Exercisable unexercised, shares | shares	301,393
Exercisable unexercised, intrinsic value | $	$ 647,696

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning balance	34,310
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 236.70
Weighted Average Life (Years), Outstanding	5 years 1 month 13 days	8 years 7 months 13 days
Aggregate Intrinsic Value, Outstanding, Beginning balance
Number of Options, Granted	45,515
Weighted Average Exercise Price, Granted	$ 3.72
Weighted Average Life (Years), Granted	3 years 4 months 28 days
Number of Options, Forfeited/Expired	(5,674)
Weighted Average Exercise Price, Forfeited/Expired	$ 54.24
Weighted Average Life (Years), Forfeited/Expired	7 years 11 months 8 days
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options Outstanding, Ending balance	74,151	34,310
Weighted Average Exercise Price, Outstanding, Ending balance	$ 107.65	$ 236.70
Aggregate Intrinsic Value, Outstanding, Ending balance
Number of Options, Options Vested and Exercisable	59,419
Weighted Average Exercise Price, Options Vested and Exercisable	$ 133.13
Weighted Average Exercise Price, Options Vested and Exercisable	4 years 2 months 15 days
Aggregate Intrinsic Value, Options Vested and Exercisable

Schedule of Outstanding Stock O

Schedule of Outstanding Stock Options (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding options	74,151
August 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 9,540
Total outstanding options	174
Expiration date	Dec. 27, 2025
September 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 9,540
Total outstanding options	36
Expiration date	Dec. 27, 2025
November 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 9,540
Total outstanding options	205
Expiration date	Dec. 27, 2025
December 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 9,540
Total outstanding options	12
Expiration date	Dec. 27, 2025
January 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 9,540
Total outstanding options	213
Expiration date	Jan. 09, 2026
May 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 12,300
Total outstanding options	45
Expiration date	May 26, 2026
September 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 12,300
Total outstanding options	21
Expiration date	May 31, 2026
January 2017 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 12,300
Total outstanding options	10
Expiration date	Jan. 01, 2027
January 2018 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 11,820
Total outstanding options	8
Expiration date	Jan. 01, 2028
January 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 564
Total outstanding options	92
Expiration date	Jan. 01, 2029
October 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 1,260
Total outstanding options	207
Expiration date	Oct. 26, 2031
January 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 844.80
Total outstanding options	111
Expiration date	Jan. 01, 2032
August 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 387.26
Total outstanding options	462
Expiration date	Aug. 23, 2032
January 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 57.60
Total outstanding options	237
Expiration date	Jan. 25, 2025
September 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 5.12
Total outstanding options	26,803
Expiration date	Sep. 12, 2033
January 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.68
Total outstanding options	8,015
Expiration date	Jan. 08, 2034
January 2024-1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price | $ / shares	$ 3.61
Total outstanding options	37,500
Expiration date	Jan. 17, 2026

Schedule of Assumptions Using B

Schedule of Assumptions Using Black-Scholes Option Pricing Mode (Details)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Risk free interest rate	3.97%
Expected Volatility	137.91%
Expected life (in years)	5 years 6 months 29 days
Expected dividend yield	0%

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value, per share		$ 2.15
Options exerciseable
Fair value		$ 34,039
Share-Based Payment Arrangement, Noncash Expense		52,681	$ 44,764
Options exerciseable value		$ 77,400
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options exerciseable		8,015
Options exerciseable value
Common Stock [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options exerciseable		37,500
Options exerciseable value		$ 77,400
Common Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares forfeited	5,674
2015 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance		629,489
Percentage of stock issued and outstanding		5%
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost		$ 24,253
Weighted average period (in years)		21 days

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)		3 Months Ended
	Sep. 27, 2023	Mar. 31, 2024	Mar. 31, 2023
Product Liability Contingency [Line Items]
Minimum bid price	$ 1
UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 500,000
Proceeds from private placement percentage		2%
License Agreement [Member]
Product Liability Contingency [Line Items]
Maintenance fees		$ 10,000
Licensed sales net		3%
License Agreement [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 10,484	$ 16,606
Diligence fee		8,000,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Feasibility Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		100,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Pivotal Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		250,000
License Agreement [Member] | UCLA TDG [Member] | Pre Market Approval of Licensed Product Or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		500,000
License Agreement [Member] | UCLA TDG [Member] | First Commercial Sale of Licensed Product or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 1,000,000
License Agreement [Member] | UCLA TDG [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		10%
License Agreement [Member] | UCLA TDG [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		20%
License Agreement [Member] | Third Party [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		0.333%
License Agreement [Member] | First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 50,000
License Agreement [Member] | After First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 250,000
License Agreement [Member] | Scenario 1 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000;
License Agreement [Member] | Scenario 2 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000; and
License Agreement [Member] | Scenario 3 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000.